Immunosuppressant Ibrutinib:Indications, Class and Drug interactions
Mar 25,2025
Ibrutinib (CAS: 936563-96-1) is a first-in-class, potent, orally administered covalently-binding inhibitor of BTK. It is a potent inhibitor of BTK that binds covalently to Cys-481 in the active site of BTK, resulting in inhibition of kinase activity.
Indications
Ibrutinibis a kinase inhibitor indicated for the treatment of adult patients with:
Mantle cell lymphoma (MCL) who have received at least one prior therapy (1.1) ;
Upon verification and description of clinical benefit in a confirmatory trial;
Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL);
Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion;
Waldenström's macroglobulinemia (WM);
Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Mechanism of Action
Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.
Side effects
The most common adverse reactions (≥30%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) are thrombocytopenia, diarrhea, fatigue, musculoskeletal pain, neutropenia, rash, anemia, and bruising. The most common adverse reactions (≥20%) in patients with cGVHD are fatigue, bruising, diarrhea, thrombocytopenia, muscle spasms, stomatitis, nausea, hemorrhage, anemia, and pneumonia.
Drug interactions
Potentially hazardous interactions with other drugs:
Anti-arrhythmics: concentration possibly increased by amiodarone and dronedarone - avoid or reduce dose of ibrutinib.
Antibacterials: concentration possibly increased by ciprofloxacin, clarithromycin, erythromycin and telithromycin - avoid or reduce dose of ibrutinib; concentration reduced by rifampicin - avoid.
Antidepressants: concentration possibly reduced by St John's wort - avoid.
Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin, phenobarbital and phenytoin - avoid.
Antifungals: concentration possibly increased by fluconazole, itraconazole, ketoconazole and voriconazole - avoid or reduce dose of ibrutinib.
Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
Antivirals: concentration possibly increased by atazanavir, darunavir, fosamprenavir, indinavir, ritonavir and saquinavir - avoid or reduce dose of ibrutinib.
Aprepitant: concentration possibly increased - avoid or reduce dose of ibrutinib.
Calcium channel blockers: concentration possibly increased by diltiazem or verapamil - avoid or reduce dose of ibrutinib.
Cobicistat: concentration possibly increased, avoid or reduce dose of ibrutinib.
Cytotoxics: concentration possibly increased by crizotinib - avoid or reduce dose of ibrutinib; concentration possibly increased by imatinib - reduce dose of ibrutinib.
Grapefruit juice and Seville oranges: avoid.
- Related articles
- Related Qustion
- BTK inhibitor Ibrutinib:Brand names,Uses,Dietary instructions and Toxicity Jul 30, 2025
Ibrutinib is a small molecule with the ability to form a covalent bond with Cys-481 in the ATP binding domain of BTK. The IC50 of ibrutinib for BTK is 0.5 nM.
- Ibrutinib: Uses, Mechanism of action and Side effects Apr 2, 2024
Ibrutinib is an oral, potent, selective and irreversible small molecule inhibitor of Btk. It is a prescription drug with the trade name IMBRUVICA?.
- Ibrutinib: A Narrative Drug Review Apr 7, 2023
Ibrutinib is an oral, irreversible covalent inhibitor of the Bruton tyrosine kinase.
Hydrocortisone acetate, a synthetic derivative of the natural steroid hormone hydrocortisone, is widely used in the pharmaceutical and healthcare industries.....
Apr 10,2025Chemical ReagentsMonocaprylin, a monoglyceride of caprylic acid, has a similar safety status and is used as an alternative food preservative.....
Mar 21,2025Food AdditivesIbrutinib
936563-96-1You may like
- Ibrutinib
-
- $1.00 / 1g
- 2025-08-02
- CAS:936563-96-1
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100kg
- Ibrutinib
-
- $0.00 / 10g
- 2025-08-01
- CAS:936563-96-1
- Min. Order: 1g
- Purity: 99% HPLC
- Supply Ability: 10000
- Ibrutinib
-
- $0.00 / 100g/Bag
- 2025-08-01
- CAS:936563-96-1
- Min. Order: 25g
- Purity: 97%-103%
- Supply Ability: 10KGS